Authorization Denials in a Hospital-Based Infusion Center
Lakeview Medical Center is a 318-bed hospital operating a 12-chair infusion center and a hospital-based oncology clinic. Payer mix is 38% Medicare Advantage, 34% commercial, 22% traditional Medicare, and 6% Medicaid or self-pay. Benefit verification is performed two business days before the appointment by a pharmacy technician. Drug prior authorization is initiated by the clinic pharmacy team, while the hospital access team handles only site-of-care authorizations. Last quarter 1,860 claims were denied, representing $2.4 million in charges. Only 410 were appealed, and 291 of those were overturned, returning $376,000. The largest denial categories were no authorization or pre-certification at 34% and medical necessity at 18%. Payer contracts require observation notification within 24 hours, but the access team typically notifies at 72 hours because the utilization review desk works Monday through Friday, 8 a.m. to 4:30 p.m., and 19% of observation admissions occur on weekends. Appeals are worked by two staff members who also answer customer service calls, so appeal volume is capped by whatever time is left at the end of the day.
1. Quantify the recoverable opportunity and recommend whether the first dollar goes to appeals capacity or denial prevention. Show your arithmetic and state your assumptions.
Read the worked answer
Arithmetic. Average charge per denied claim is $2.4M divided by 1,860, or about $1,290. Of the 1,860 denials, 410 were appealed, leaving 1,450 unappealed. If the 71% overturn rate on appealed claims roughly holds for the unappealed pool, potential recovery is 1,450 x 0.71 x $1,290, or roughly $1.33 million in charges. That figure must be discounted to cash: at an assumed 30% net collection rate on charges, the cash value is approximately $400,000. State both numbers and label the 30% as an assumption drawn from the hospital's own net-to-gross, because presenting charges as cash will destroy credibility with finance.
Recommendation: do both, but in a deliberate order. Appeals carry a proven 71% yield on money already spent and already documented, so a time-limited surge makes sense: 90 days of contract or overtime appeal support, worked by highest value first and by timely-filing deadline, restricted to the two largest denial categories. That is a rental, not a permanent cost.
Prevention is the durable fix. An appealed claim consumes $25 to $50 in rework, delays cash 60 to 90 days, and has a 29% chance of total loss. Weekend utilization review coverage and a pre-service authorization check attack the 34% no-auth category directly. The judgement the exam is testing is that appeals are a one-time recovery of a self-inflicted wound, and permanent staff should be pointed at prevention.
2. Design three leading indicators that would predict authorization denials before the claim is billed.
Read the worked answer
Leading indicators must be measurable before service, tied to a named owner, and capable of changing behavior that week.
1. Percentage of scheduled infusion and clinic cases with authorization on file three business days before the appointment. Target 95% or higher, reported by payer and by regimen. This exposes the drug prior authorization gap that the two-business-day verification cycle cannot absorb, since specialty drug authorizations frequently take longer than two days. Owner: pharmacy prior authorization team, with the access team flagging cases that arrive without a documented auth number.
2. Observation notification completed within 24 hours, stratified by day of week. Target 100%, with weekend and holiday admissions reported separately. Reporting a single blended rate hides the 19% weekend volume that the Monday-to-Friday desk structurally cannot reach, and blending is how organizations convince themselves a problem does not exist.
3. Authorization denial rate by payer and by denial category, measured on a rolling four-week basis rather than quarterly. Quarterly data arrives too late to correct a payer-specific pattern; a four-week view lets contract management raise a systemic issue with the plan while claims are still appealable.
Add a companion volume metric: count of cases in the pre-service worklist flagged as high denial risk. It gives the supervisor a daily queue to work rather than a monthly postmortem.
3. The pharmacy director argues drug authorizations belong entirely to pharmacy and that access should stay out of clinical authorizations. How should ownership be divided, and how would you make that division enforceable?
Read the worked answer
The pharmacy director is largely right on substance and wrong on isolation. Split ownership by decision type, then make the handoff a hard stop.
Pharmacy owns clinical drug authorizations: regimen selection, medical necessity documentation, peer-to-peer review, and drug-specific appeal content. This is clinical judgement and belongs with pharmacists.
Access owns eligibility verification, site-of-care and facility authorization, benefit design questions including which drug is on which tier or requires step therapy, financial clearance, patient liability estimates, and the scheduling decision about whether to book a case without a documented auth. Access also owns the data field that says the auth exists, because access is the department that will be blamed when it does not.
Utilization review owns observation notification timing, including weekend coverage.
Revenue cycle owns appeal strategy and payer escalation.**
Make it enforceable through three mechanisms. First, a single auth status field in the EHR with defined values, so there is one version of truth instead of two departments each believing the other checked. Second, a scheduling rule that blocks booking an infusion appointment without an auth number except through a documented exception with an approver name. Third, a weekly 20-minute denial huddle with a shared dashboard that shows auth-on-file performance by owner, so the conversation is about numbers rather than territory. Escalate payer patterns to contract management jointly, not separately.